Comparative Efficacy of Chhinnadi Kwath and Devdarvyadi Ghrit Nasya in the Management of Ardhavabhedaka (Migraine): A Randomized Clinical Trial
Abstract
Background: Ardhavabhedaka, a medical condition which is mentioned in ancient Ayurvedic texts, which is similar to migraine, is a common neurological ailment that leads to considerable disability. Ayurveda provides a variety of treatment options, such as oral decoctions (Kwath) and nasal therapies (Nasya).
Objective: To evaluate the therapeutic effects of oral Chhinnadi Kwath and Devdarvyadi Ghrit Nasya in the treatment of Ardhavabhedaka.
Methods: A clinical trial with a randomized, open-label, parallel-group design was carried out involving 30 diagnosed participants, who were evenly divided into two groups. Group A was administered Chhinnadi Kwath (48 ml orally twice a day), while Group B received Devdarvyadi Ghrit Nasya (6 drops in each nostril every morning). The treatment lasted for 60 days. The primary outcomes assessed were changes in the severity, duration, and frequency of attacks, evaluated on a scale from 0 to 4. Statistical analysis was conducted using suitable non-parametric tests, such as the Chi-square and Fisher’s exact test, along with paired t-tests.
Results: Both groups experienced statistically significant enhancements in all pain metrics from the initial assessment (p0.05). The baseline demographic characteristics were mostly similar, although there were significant differences in Ayurvedic parameters such as Koshtha (bowel type, p=0.027) and Prakriti (body constitution, p=0.004).
Conclusion: Both Chhinnadi Kwath and Devdarvyadi Ghrit Nasya are effective…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 30 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.